Rating Rationale
July 05, 2019 | Mumbai
Kremoint Pharma Private Limited
Ratings Reaffirmed
 
Rating Action
Total Bank Loan Facilities Rated Rs.15 Crore
Long Term Rating CRISIL BBB-/Stable (Reaffirmed)
Short Term Rating CRISIL A3 (Reaffirmed)
1 crore = 10 million
Refer to annexure for Details of Instruments & Bank Facilities
Detailed Rationale

CRISIL has reaffirmed its 'CRISIL BBB-/Stable/CRISIL A3' ratings on bank facilities of Kremoint Pharma Private Limited (KPPL; part of Kremoint group).

The ratings continue to reflect extensive experience of its promoters in pharmaceutical industry, established relationship with customers and above-average financial risk profile. These rating strengths are partially offset by the modest scale of operations, large working capital requirements and exposure to geographical concentration risk.

Analytical Approach

For arriving at the ratings, CRISIL has consolidated the business and financial risk profiles of KPPL and its 60% subsidiary, Eco-Rich Cosmetic India Private Limited (Eco-Rich). That's because these entities, collectively referred to as the Kremoint group, have common promoters, are in the same line of business, and have significant operational, managerial and financial linkages.

Please refer Annexure - List of entities consolidated, which captures the list of entities considered and their analytical treatment of consolidation. 

Key Rating Drivers & Detailed Description
Strengths:
* Extensive experience of promoters in the pharmaceutical formulation sector:
The two decade-long experience of the promoter, in the pharmaceutical sector, has helped the group develop its product line and clientele. The group manufactures a wide range of formulations used in various therapeutic segments. This has led to increase in revenues to Rs. 43.9 crore in fiscal 2019, from Rs. 32.5 crore in fiscal 2018.

* Above-average financial risk profile: Gearing was low at 0.47 times and total outside liabilities to adjusted net-worth (TOLANW) was moderate at 1.1 times, as on March 31, 2019. There is low dependence on debt as working capital requirement is largely met via internal accruals. Interest coverage and net cash accrual to adjusted debt ratios were above average, at 4.5 times and 0.29 time, respectively, for fiscal 2019. Financial profile is expected to remain comfortable in the medium term.

Weaknesses:
* Modest scale of operations:
Kremoint group's modest scale is as reflected in revenue of Rs 43.9 crore for fiscal 2019. This is commensurate with its capacity, limited reach of products and intense competition. This has also constrained operating margins, which have declined from 19.7% in fiscal 2017 to 10.2% in fiscal 2019.

* Exposure to geographical concentration risk: Kremoint group derives over 85% of its revenue from African countries such as Congo, Mali, Cote D'lvoire, Senegal, Nigeria and South Africa, exposing it to geographical concentration risk. Any regulatory changes, or change in the procurement policies of these countries or occurrence of any event impacting the offtake, could impact the business risk profile.

* Working capital-intensive operations: The operations are working capital intensive, as reflected in the gross current assets of 247 days as on March 31, 2019, driven by high receivables of around 90 days and Rs 7 crore of cash balances. Most of the working capital requirement is funded through creditors, leading to moderate reliance on bank lines, as indicated by bank limit utilisation of 56% over 12 months through April 2018.
Liquidity

Kremoint group has adequate liquidity driven by expected cash accruals of around Rs. 4.5-6 crores in fiscal 2020 and fiscal 2021, and cash and cash equivalents of Rs. 12 crores as on March 31, 2019. KPPL also has access to fund based limits of Rs. 3.5 crores, which was utilized to the tune of 56% on average over the 12 months ended February 2019. The group has long term repayment obligations of Rs. 0.6 crores in each of fiscal 2020 and fiscal 2021 and no major capex plans. CRISIL expects internal accruals, cash & cash equivalents and cushion in bank lines to be sufficient to meet its incremental working capital requirements.

Outlook: Stable

CRISIL believes the Kremoint group will continue to benefit from above-average financial risk profile and strong market presence. The outlook may be revised to 'Positive' if significant growth in revenue and profitability and better working capital management, leads to better financial risk profile. The outlook might be revised to 'Negative' if decline in revenue or profitability, any large capital expenditure or stretch in the working capital cycle, weakens financial risk profile, especially liquidity.

About the Group

KPPL, incoporated in January 1993, manufactures ointments, creams, and gels in allopathic medicines for external usage. The manufacturing facility is at MIDC Ambernath, (Thane). Mr Bhadresh Thakkar holds 30% stake in KPPL, while Bliss GVS Pharma Ltd (Bliss; rated 'CRISIL BBB/Stable/CRISIL A3+') holds the balance stake.
 
Eco-Rich, incorporated in January 2013, manufactures cosmetic and personal care products, at its manufacturing facility in Wada, Thane. The founder, Mr Anup Jain holds 33% stake in Eco-Rich, while KPPL owns 60%.

Key Financial Indicators
Particulars Unit 2019 2018
Revenue Rs. crore 43.89 32.54
Profit after tax (PAT) Rs. crore 2.99 3.41
PAT margin % 6.8 10.5
Adjusted debt/Adjusted networth Times 0.47 0.42
Interest coverage Times 4.52 14.26
*Provisional numbers

Any other information: Not applicable

Note on complexity levels of the rated instrument:
CRISIL complexity levels are assigned to various types of financial instruments. The CRISIL complexity levels are available on www.crisil.com/complexity-levels. Users are advised to refer to the CRISIL complexity levels for instruments that they consider for investment. Users may also call the Customer Service Helpdesk with queries on specific instruments.
Annexure - Details of Instrument(s)
ISIN Name of Instrument Date of Allotment Coupon
Rate (%)
Maturity Date Issue
Size (Rs. Cr)
Rating Assigned  with Outlook
NA Cash Credit NA NA NA 3.5 CRISIL BBB-/Stable
NA Bill Purchase NA NA NA 5 CRISIL A3
NA Packing Credit NA NA NA 2 CRISIL A3
NA Proposed long term bank facilities NA NA NA 4.5 CRISIL BBB-/Stable

Annexure - List of entities consolidated
Names of Entities Consolidated Extent of Consolidation Rationale for Consolidation
Kremoint Pharma Private Limited Fully consolidated Strong business and financial linkages
Eco-Rich Cosmetic India Private Limited Fully consolidated Strong business and financial linkages
Annexure - Rating History for last 3 Years
  Current 2019 (History) 2018  2017  2016  Start of 2016
Instrument Type Outstanding Amount Rating Date Rating Date Rating Date Rating Date Rating Rating
Fund-based Bank Facilities  LT/ST  18.00  CRISIL BBB-/Stable/ CRISIL A3      30-06-18  CRISIL BBB-/Stable/ CRISIL A3  29-03-17  CRISIL BBB-/Stable/ CRISIL A3      CRISIL BB+/Positive/ CRISIL A4+ 
Non Fund-based Bank Facilities  LT/ST    --    --    --  29-03-17  CRISIL A3      CRISIL A4+ 
All amounts are in Rs.Cr.
Annexure - Details of various bank facilities
Current facilities Previous facilities
Facility Amount (Rs.Crore) Rating Facility Amount (Rs.Crore) Rating
Bill Purchase 5 CRISIL A3 Bill Purchase 5 CRISIL A3
Cash Credit 3.5 CRISIL BBB-/Stable Cash Credit 3.5 CRISIL BBB-/Stable
Packing Credit 2 CRISIL A3 Packing Credit 2 CRISIL A3
Proposed Long Term Bank Loan Facility 4.5 CRISIL BBB-/Stable Proposed Long Term Bank Loan Facility 4.5 CRISIL BBB-/Stable
Total 15 -- Total 15 --
Links to related criteria
CRISILs Approach to Financial Ratios
CRISILs Bank Loan Ratings - process, scale and default recognition
Rating criteria for manufaturing and service sector companies
Rating Criteria for the Pharmaceutical Industry
CRISILs Criteria for Consolidation
CRISILs Criteria for rating short term debt

For further information contact:
Media Relations
Analytical Contacts
Customer Service Helpdesk
Saman Khan
Media Relations
CRISIL Limited
D: +91 22 3342 3895
B: +91 22 3342 3000
saman.khan@crisil.com

Naireen Ahmed
Media Relations
CRISIL Limited
D: +91 22 3342 1818
B: +91 22 3342 3000
naireen.ahmed@crisil.com

Vinay Rajani
Media Relations
CRISIL Limited
D: +91 22 3342 1835
M: +91 91 676 42913
B: +91 22 3342 3000
vinay.rajani@ext-crisil.com

Mohit Makhija
Director - CRISIL Ratings
CRISIL Limited
B:+91 124 672 2000
mohit.makhija@crisil.com


Ankita Gupta
Associate Director - CRISIL Ratings
CRISIL Limited
D:+91 22 4097 8104
ankita.gupta@crisil.com


Prayag Sinha
Rating Analyst - CRISIL Ratings
CRISIL Limited
B:+91 22 3342 3000
Prayag.Sinha@crisil.com
Timings: 10.00 am to 7.00 pm
Toll free Number:1800 267 1301

For a copy of Rationales / Rating Reports:
CRISILratingdesk@crisil.com
 
For Analytical queries:
ratingsinvestordesk@crisil.com


 

Note for Media:
This rating rationale is transmitted to you for the sole purpose of dissemination through your newspaper / magazine / agency. The rating rationale may be used by you in full or in part without changing the meaning or context thereof but with due credit to CRISIL. However, CRISIL alone has the sole right of distribution (whether directly or indirectly) of its rationales for consideration or otherwise through any media including websites, portals etc.


About CRISIL Limited

CRISIL is a leading agile and innovative, global analytics company driven by its mission of making markets function better. We are India’s foremost provider of ratings, data, research, analytics and solutions. A strong track record of growth, culture of innovation and global footprint sets us apart. We have delivered independent opinions, actionable insights, and efficient solutions to over 1,00,000 customers.
 
We are majority owned by S&P Global Inc., a leading provider of transparent and independent ratings, benchmarks, analytics and data to the capital and commodity markets worldwide.
 
For more information, visit www.crisil.com 


Connect with us: TWITTER | LINKEDIN | YOUTUBE | FACEBOOK

About CRISIL Ratings
CRISIL Ratings is part of CRISIL Limited (“CRISIL”). We pioneered the concept of credit rating in India in 1987. CRISIL is registered in India as a credit rating agency with the Securities and Exchange Board of India (“SEBI”). With a tradition of independence, analytical rigour and innovation, CRISIL sets the standards in the credit rating business. We rate the entire range of debt instruments, such as, bank loans, certificates of deposit, commercial paper, non-convertible / convertible / partially convertible bonds and debentures, perpetual bonds, bank hybrid capital instruments, asset-backed and mortgage-backed securities, partial guarantees and other structured debt instruments. We have rated over 24,500 large and mid-scale corporates and financial institutions. CRISIL has also instituted several innovations in India in the rating business, including rating municipal bonds, partially guaranteed instruments and microfinance institutions. We also pioneered a globally unique rating service for Micro, Small and Medium Enterprises (MSMEs) and significantly extended the accessibility to rating services to a wider market. Over 1,10,000 MSMEs have been rated by us.


CRISIL PRIVACY
 
CRISIL respects your privacy. We may use your contact information, such as your name, address, and email id to fulfil your request and service your account and to provide you with additional information from CRISIL.For further information on CRISIL’s privacy policy please visit www.crisil.com.


DISCLAIMER

This disclaimer forms part of and applies to each credit rating report and/or credit rating rationale that we provide (each a “Report”). For the avoidance of doubt, the term “Report” includes the information, ratings and other content forming part of the Report. The Report is intended for the jurisdiction of India only. This Report does not constitute an offer of services. Without limiting the generality of the foregoing, nothing in the Report is to be construed as CRISIL providing or intending to provide any services in jurisdictions where CRISIL does not have the necessary licenses and/or registration to carry out its business activities referred to above. Access or use of this Report does not create a client relationship between CRISIL and the user.

We are not aware that any user intends to rely on the Report or of the manner in which a user intends to use the Report. In preparing our Report we have not taken into consideration the objectives or particular needs of any particular user. It is made abundantly clear that the Report is not intended to and does not constitute an investment advice. The Report is not an offer to sell or an offer to purchase or subscribe for any investment in any securities, instruments, facilities or solicitation of any kind or otherwise enter into any deal or transaction with the entity to which the Report pertains. The Report should not be the sole or primary basis for any investment decision within the meaning of any law or regulation (including the laws and regulations applicable in the US).

Ratings from CRISIL Rating are statements of opinion as of the date they are expressed and not statements of fact or recommendations to purchase, hold, or sell any securities / instruments or to make any investment decisions. Any opinions expressed here are in good faith, are subject to change without notice, and are only current as of the stated date of their issue. CRISIL assumes no obligation to update its opinions following publication in any form or format although CRISIL may disseminate its opinions and analysis. CRISIL rating contained in the Report is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment or other business decisions. The recipients of the Report should rely on their own judgment and take their own professional advice before acting on the Report in any way.CRISIL or its associates may have other commercial transactions with the company/entity.

Neither CRISIL nor its affiliates, third party providers, as well as their directors, officers, shareholders, employees or agents (collectively, “CRISIL Parties”) guarantee the accuracy, completeness or adequacy of the Report, and no CRISIL Party shall have any liability for any errors, omissions, or interruptions therein, regardless of the cause, or for the results obtained from the use of any part of the Report. EACH CRISIL PARTY DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY, SUITABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. In no event shall any CRISIL Party be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs) in connection with any use of any part of the Report even if advised of the possibility of such damages.

CRISIL Ratings may receive compensation for its ratings and certain credit-related analyses, normally from issuers or underwriters of the instruments, facilities, securities or from obligors. CRISIL’s public ratings and analysis as are required to be disclosed under the regulations of the Securities and Exchange Board of India (and other applicable regulations, if any) are made available on its web sites, www.crisil.com (free of charge). Reports with more detail and additional information may be available for subscription at a fee – more details about CRISIL ratings are available here: www.crisilratings.com.

CRISIL and its affiliates do not act as a fiduciary. While CRISIL has obtained information from sources it believes to be reliable, CRISIL does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives and / or relies in its Reports. CRISIL keeps certain activities of its business units separate from each other in order to preserve the independence and objectivity of the respective activity. As a result, certain business units of CRISIL may have information that is not available to other CRISIL business units. CRISIL has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process. CRISIL has in place a ratings code of conduct and policies for analytical firewalls and for managing conflict of interest. For details please refer to: https://www.crisil.com/en/home/our-businesses/ratings/regulatory-disclosures/highlighted-policies.html

CRISIL’s rating criteria are generally available without charge to the public on the CRISIL public web site, www.crisil.com. For latest rating information on any instrument of any company rated by CRISIL you may contact CRISIL RATING DESK at CRISILratingdesk@crisil.com, or at (0091) 1800 267 1301.

This Report should not be reproduced or redistributed to any other person or in any form without a prior written consent of CRISIL.

All rights reserved @ CRISIL